1. Giacomet V, Cococcioni L, Pisanelli S, Benincaso AR, Nannini P, Genoni T, et al. Management of newborn at risk of neonatal and perinatal tuberculosis. Asian Pac J Trop Dis. 2017;7(9):569-71.
2. Subuh M, Priohutomo S, Widaningrum C, Dinihari N, Siagian V, Uyainah A, et al. Pedoman Nasional Pengendalian Tuberkulosis. Jakarta: Kementerian Kesehatan RI. 2014
3. El-Messidi A, Czuzoj-Shulman N, Spence AR, Abenhaim HA. Medical and obstetric outcomes among pregnant women with tuberculosis: a population-based study of 7.8 million births. Am J Obstet Gynecol 2016; 215:797.e1.
4. Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: Epidemiology, Management, and Research Gaps. CID. 2012;55(1):1532-49.
5. Nguyen HT, Pandolfini C, Chiodini P, Bonati M. Tuberculosis care for pregnant women: a systematic review. BMC Infectious Disease. 2014;14:617.
6. Palacios E, Dallman R, Muñoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru. Clin Infect Dis 2009;48(10):1413-9.
7. Repossi AC, Bothamley GH. Tuberculosis and Pregnancy: an Updated Systematic Review. Pulm Res Respir Med Open J. 2015: 63-6.
8. https://www.cdc.gov/tb/topic/treatment/pregnancy.htm
9. WHO. Annex 6 Essential first-line antituberculosis drugs. In : Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update
10. CDC. Latent tuberculosis infection: A guide for primary health care providers. 2016. https://www.cdc.gov/tb/publications/ltbi/treatment.htm
11. Nahid P, lipanah N, Dorman SE, Barry PM, Brozek JL, Cattamanchi A, et al. ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible TB. CID. 2016:34.
12. Herchline TE, Amorosa JK. What is immune reconstitution inflammatory syndrome (IRIS) in patients receiving treatment for tuberculosis (TB) and HIV infection?. Medscape. 2018
13. Kemenkes RI. Peraturan Menteri Kesehatan Republik Indonesia No. 67 Tahun 2016 Tentang Penanggulangan Tuberkulosis. Kemenkes RI. 2016: 111